Pharming B.V.
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Industrial and Commercial Machinery and Equipment, Not Elsewhere Classified), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Pharming B.V.
Live alerts from global media, monitored by Business Radar
2025-01-07 (iex.nl)
DWS reports greater interest in Pharming
DWS Investment has reported a larger stake in Pharming Group. This emerged from a notification in the context of the Financial Supervision Act, dated January 3, 2025.
Read more
2025-01-07 (iex.nl)
DWS reports greater interest in Pharming
DWS Investment has reported a larger stake in Pharming Group. This emerged from a notification in the context of the Financial Supervision Act, dated January 3, 2025.
Read more
2024-12-13 (iex.nl)
Fundlogic reports interest in Pharming
Fundlogic SAS has announced its first interest in Pharming Group. This emerged from a notification in the context of the Financial Supervision Act, dated December 11, 2024.
Read more
1998-04-27 (nrc.nl)
ABN Amro and NPM Capital invest in Pharming
ROTTERDAM, APRIL 28. The investment companies ABN Amro Participaties and NPM Capital have invested 13 and 11 million guilders respectively in the Leiden biotechnological company Pharming. The company became independent in April '95, and which received publicity at the time due to the transgenic bull H
Read more
1998-04-27 (nrc.nl)
ABN Amro and NPM Capital invest in Pharming
ROTTERDAM, APRIL 28. The investment companies ABN Amro Participaties and NPM Capital have invested 13 and 11 million guilders respectively in the Leiden biotechnological company Pharming. The company became independent in April '95, and which received publicity at the time due to the transgenic bull H
Read more
1998-04-27 (nrc.nl)
ABN Amro and NPM Capital invest in Pharming
ROTTERDAM, APRIL 28. The investment companies ABN Amro Participaties and NPM Capital have invested 13 and 11 million guilders respectively in the Leiden biotechnological company Pharming. The company became independent in April '95, and which received publicity at the time due to the transgenic bull H
Read more